New York New York (PRWEB) September 04 2013 Thousands of Actos lawsuits ( http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html ) that allege long-term use of the Type 2 diabetes drug caused patients to develop bladder cancer continu

Thousands of Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) that allege long-term use of the Type 2 diabetes drug caused patients to develop bladder cancer continue to move forward in courts throughout the country, Bernstein Liebhard LLP reports. According to court documents, opening statements in the nation’s second trail involving Actos bladder cancer allegations got underway yesterday in Maryland state court, with a lawyer for the Plaintiff accusing Takeda Pharmaceutical Co. of placing the drug’s sales ahead of patient safety. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

“Our Firm continues to hear from long-term Actos users whose experiences with the medication echo the allegations that will be put forth during this trial. We hope this proceeding will provide valuable insights into the way juries could rule in similar Actos lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of Actos.

Actos Lawsuits

Court documents indicate that more than 3,000 Actos bladder cancer claims are currently pending in courts throughout the U.S., the majority of which have been filed in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. That litigation’s first bellwether trial will begin on January 27, 2014, while the second will commence on April 14, 2014. (In re: Actos Product Liability Litigation, MDL No. 2299)

The case underway in Maryland was filed on behalf of a Vietnamese immigrant who died of bladder cancer last year. During yesterday’s opening statements in Baltimore, the Plaintiffs’ attorney told the jury that Takeda knew by 2005 that research had linked long-term use of Actos to bladder cancer, but waited six years to issue a public warning. This delay allowed the company to increase sales of the drug, the lawyer asserted. The decedent’s family alleges that his long-term use of Actos resulted in his diagnosis of high-grade bladder cancer in September 2011.

Actos lawsuits have been mounting since June 2011, when the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer. The first state trial involving Actos and bladder cancer concluded this past April in Los Angeles Superior court, with that jury awarding more than $6 million to a man who was diagnosed with bladder cancer after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Long-term users of Actos who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...

(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...

(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...

(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...

(Date:12/8/2016)... Pa. , Dec. 8, 2016 Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...